Volume : 13, Issue : 04, April – 2026
Title:
DEVELOPMENT, OPTIMIZATION AND CHARACTERIZATION OF ROSUVASTATIN SOLID LIPID NANOPARTICLES EMPLOYING 3² FACTORIAL DESIGN
Authors :
P. Prakash *, K R Sai Lakshmi
Abstract :
The purpose of this study was to development, optimization and characterization of rosuvastatin solid lipid nanoparticles employing 3² factorial design. rosuvastatin loaded solid lipid nanoparticles, was prepared by hot homogenization technique followed by ultra sonication method. Factorial design was introduced to optimize the formulation of solid lipid nanoparticles Results: Differential scanning calorimetry & Powder X-Ray Diffractometry studies indicate that the excipients added were compatible with the drug. The value of zeta potential Zeta potential value > ± 30 mV is essential for effective stability and to inhibit aggregation of particles. The low polydispersity index in all the formulations indicated the homogeneity of the particle size. Highest entrapment efficiency of 97.4% was observed for tristearin based SLN. The scanning electron nanometer-size and spherical in shape and mono-dispersed SLN with spherical shape.
Key words: Solid lipid nanoparticles, ultra sonication, Factorial design & Differential scanning calorimetry.
Cite This Article:
Please cite this article in press P. Prakash et al., Development, Optimization And Characterization Of Rosuvastatin Solid Lipid Nanoparticles Employing 3² Factorial Design., Indo Am. J. P. Sci, 2026; 13(04).
REFERENCES:
1. Demirel M, Yazan Y, Muller R H. Kilic F, Bozan B, Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. 2001; 18(3): 359-371.
2. Der VanLinde A. Statistical comment on a new method for noncompartmental pharmacokinetic analysis. Biometrical Journal. 1988; 30: 123-127.
3. Dhiman M K, Yedurkar P D, Sawant K K. Buccal bioadhesive delivery system of 5-fluorouracil: Optimization and characterization. Drug Dev Ind Pharm. 2008; 34: 761–770.
4. Doijad R C, Manvi F V, Godhwani D M, Joseph R, and Deshmukh N V. Formulation and Targeting Efficiency of Cisplatin Engineered Solid Lipid Nanoparticles. Indian J. Pharm. Sci. 2008; 70(2): 203–207.Han C, Qi CM, Zhao BK, Cao J, Xie SY, Wang SL, Zhou WZ. Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J Veter Pharmacol Ther. 2009 Apr;32(2):116-23.
5. Boistelle R, Fundamentals of nucleation and crystal growth, in: Garti N, Sato K. (Eds.), Crystallization and Polymorphism of Fats and Fatty Acids, Marcel Dekker Inc. New York, Basel, 1988; 189–226.
6. Bunjes H, Siekmann B, Westesen K. Emulsions of super- cooled melts
7. — a novel drug delivery system, in: S. Benita (Ed.), Submicron Emulsions in Drug Targeting and Delivery, Harwood Academic Publishers, Amsterdam, 1998; 175-204.
8. Carlucci G, Mazzeo P, Biordi L, Bologna M. Simultaneous determination of Rosuvastatin and its hydroxyl acid form in human plasma by HPLC with UV detection. J. Pharm. Biomed. Anal. 1992; 10: 693-697
9. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effect of some experimental factors on the production process of solid lipid nanoparticles, Eur. J. Pharm. Biopharm. 1996; 43: 110–115.
10. Oussoren C, Zuidema J, Crommelin DJ, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection.: II. Influence of liposomal size, lipid composition and lipid dose. Biochimica et Biophysica Acta- Biomembranes. 1997 Sep 4;1328(2):261-72.
11. Freitas C, Muller R H. Stability determination of solid lipid nanoparticles (SLNTM) in aqueous dispersion after addition of electrolyte. J. Microencapsul. 1999; 16: 59–71.
12. Freitas RH, Muller, Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J of Pharm and Biopharm.1999; 125–132.
13. Freitas C, Muller R H, Spray-drying of solid lipid nanoparticles (SLN).Eur. J. Pharm. Biopharm. 1998; 46: 145–151.
14. Friedrich I, Muller-Goymann C, Characterization of solidified reverse micellar solutions (SRMS) and production development of SRMS- based nano suspensions. Eur. J. Pharm. Biopharm. 2003; 56 (1): 111-119.
15. Frosch P J, Kligman A M. The chamber-scarification test for irritancy., Contact Dermatitis 1976; 2: 314–324.
16. John J Bojjola and Lonnie D Russell. In, Electron microscopy principles and techniques for biologists. 2ndEd. 1998, 132-133.
17. Jumaa M, Muller B W. Lipid emulsions as a novel system to reduce the hemolytic activity oflytic agents: mechanism of protective effect. Eur. J. Pharm. Sci. 2000; 9: 285-290.
18. Khan H, Ali M, Ahuja A and Ali J. Stability testing of pharmaceutical products-comparison of stability testing guidelines. Curr Pharm Anal. 2010; 6: 142-150.
19. Angelis D G. Influence of statin characteristics on their safety and tolerability. Int. J. Clin. Pract. 2004; 58; 945–955.
20. Arjun N and Kishan V. Preparation, Characterization and Evaluation of Quetiapine Fumarate Solid Lipid Nanoparticles to Improve the Oral Bioavailability, Journal of Pharmaceutics.2013; 1- 7.
21. Augsten C, Kiselev M A, Gehrke R, Hause G, Mader K. A detailed analysis of biodegradable nanospheres by different techniques–A combined approach to detect particle sizes and size distributions. J. Pharm. Biomed. Anal. 2008; 47: 95-102..